No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer

Jenkins, V A and Fallowfield, L J (2016) No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer. Supportive Care in Cancer, 24 (11). pp. 4471-4473. ISSN 0941-4355

[img] PDF - Accepted Version
Download (234kB)

Abstract

The majority of men treated for prostate cancer will eventually develop castrate resistant disease (CRPC) with metastases (mCRPC). There are several options for further treatment: chemotherapy, third-line hormone therapy, radium, immunotherapy and palliation. Current ASCO guidelines for survivors of prostate cancer recommend that an individual’s information needs at all stages of disease are assessed, and that patients are provided with or referred to the appropriate sources for information and support. Earlier reviews have highlighted the dearth of such services and we wished to see if the situation had improved more recently. Unfortunately we conclude that there is still a lack of good quality congruent information easily accessible specifically for men with mCRPC and insufficient data regarding the risks, harms and benefits of different management plans. More research providing a clear evidence base about treatment consequences using patient reported outcome measures is required.

Item Type: Article
Keywords: Metastatic castrate resistant prostate cancer, Information needs, decision making, treatment
Schools and Departments: Brighton and Sussex Medical School > Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Subjects: B Philosophy. Psychology. Religion > BF Psychology
R Medicine
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens
Depositing User: Kathryn Monson
Date Deposited: 04 Aug 2016 14:01
Last Modified: 30 Jul 2017 03:21
URI: http://sro.sussex.ac.uk/id/eprint/62221

View download statistics for this item

📧 Request an update
Project NameSussex Project NumberFunderFunder Ref
EXPECTG1580pH Associates and SanofiUnset